Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.
We evaluated the recent prevalence of antimicrobial-resistant Haemophilus influenzae isolated from the upper respiratory tracts (URT) of patients in Japan. Mutations in the ftsI gene, which encodes penicillin binding protein 3 (PBP3), and the clonal dissemination of the resistant strains were also investigated. A total of 264 H. influenzae isolates were collected from patients with URT infections. According to the criteria of the Clinical and Laboratory Standards Institute for the susceptibility of H. influenzae to ampicillin (AMP), the isolates were distributed as follows: 161 (61.0%) susceptible strains (MIC < or = 1 microg/ml), 37 (14.0%) intermediately resistant strains (MIC = 2 microg/ml), and 66 (25.0%) resistant strains (MIC > or = 4 microg/ml). According to PCR-based genotyping, 172 (65.1%) of the isolates had mutations in the ftsI gene and were negative for the beta-lactamase (bla) gene. These 172 isolates were thus defined as genetically beta-lactamase-negative ampicillin-resistant (gBLNAR) strains. The ftsI mutant group included 98 (37.1%) strains with group I/II mutations in the variable mutated region (group I/II gBLNAR) and 74 (28.0%) strains with group III mutations in the highly mutated region (group III gBLNAR). Eighty-seven (33.0%) of the isolates were genetically beta-lactamase-negative ampicillin-susceptible (gBLNAS) strains. The group III gBLNAR strains showed resistance to beta-lactams. Only five strains (1.9%) were positive for a bla gene encoding TEM-type beta-lactamase. The three clusters consisting of 16 strains found among the 61 BLNAR strains (MIC > or = 4 microg/ml and without the bla gene) showed identical or closely related DNA restriction fragment patterns. Those isolates were frequently identified among strains with a MIC to AMP of 16 microg/ml. The current study demonstrates the apparent dissemination and spread of a resistant clone of H. influenzae among medical centers in Japan. The gBLNAR strains show a remarkable prevalence among H. influenzae isolates, with the prevalence increasing with time. This fact should be taken into account when treating URT infections.
Hotomi
Muneki
M
Department of Otolaryngology-Head and Neck Surgery, Wakayama Medical University, 811-1 Kimiidera, Wakayama-shi, Wakayama, 641-8509, Japan.
Fujihara
Keiji
K
Billal
Dewan S
DS
Suzuki
Kenji
K
Nishimura
Tadao
T
Baba
Shunkichi
S
Yamanaka
Noboru
N
D000293:Adolescent; D000328:Adult; D000667:Ampicillin / Q000494:pharmacology*; D000668:Ampicillin Resistance / Q000235:genetics; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002648:Child; D002675:Child, Preschool; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006193:Haemophilus influenzae / Q000187:drug effects* / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007564:Japan; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009154:Mutation; D016133:Polymerase Chain Reaction; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D001618:beta-Lactamases / Q000235:genetics
D000900:Anti-Bacterial Agents; D000667:Ampicillin; D001618:beta-Lactamases
J Antimicrob Chemother. 1996 Apr;37(4):737-46
8722539
Diagn Microbiol Infect Dis. 1997 Mar;27(3):75-83
9147008
J Antimicrob Chemother. 1998 Feb;41(2):253-8
9533468
J Clin Microbiol. 1998 Dec;36(12):3629-35
9817886
Chemotherapy. 1999 Jan-Feb;45(1):15-21
9876205
Antimicrob Agents Chemother. 1999 Feb;43(2):385-9
9925540
ORL J Otorhinolaryngol Relat Spec. 2004;66(5):233-40
15583436
Acta Otolaryngol. 2005 Feb;125(2):180-3
15880950
J Antimicrob Chemother. 2005 Jul;56(1):133-8
15917287
Acta Otolaryngol. 2006 Feb;126(2):130-7
16428188
Jpn J Infect Dis. 2006 Feb;59(1):36-41
16495632
Antimicrob Agents Chemother. 2006 Jul;50(7):2487-92
16801430
J Antimicrob Chemother. 2006 Oct;58(4):873-7
16891323
J Infect Dis. 2007 Jan 1;195(1):81-9
17152011
Antimicrob Agents Chemother. 2007 Feb;51(2):453-60
17116681
Epidemiol Infect. 2007 May;135(4):665-8
16953950
Antimicrob Agents Chemother. 2007 Sep;51(9):3463-4
17606681
Antimicrob Agents Chemother. 2001 May;45(5):1585-8
11302835
Antimicrob Agents Chemother. 2001 Jun;45(6):1693-9
11353613
Antimicrob Agents Chemother. 2001 Nov;45(11):3226-8
11600386
J Antimicrob Chemother. 2001 Nov;48(5):723-6
11679563
J Clin Microbiol. 2002 Mar;40(3):1063-6
11880440
J Infect Chemother. 2003 Mar;9(1):46-52
12673407
Microb Drug Resist. 2003 Spring;9(1):39-46
12705682
J Antimicrob Chemother. 2003 Dec;52(6):1018-21
14585854
Antimicrob Agents Chemother. 2004 May;48(5):1509-14
15105098
Antimicrob Agents Chemother. 2004 May;48(5):1630-9
15105114
Lancet. 1974 Feb 23;1(7852):313
4130492
Antimicrob Agents Chemother. 1980 Jan;17(1):80-3
6965443
Antimicrob Agents Chemother. 1984 Aug;26(2):235-44
6333208
Diagn Microbiol Infect Dis. 1986 Feb;4(2):95-107
3485505
Infect Immun. 1987 Nov;55(11):2585-9
3499396
J Antimicrob Chemother. 1987 Nov;20(5):645-56
3501421
J Antimicrob Chemother. 1990 Apr;25(4):525-34
2351623
Antimicrob Agents Chemother. 1992 Jul;36(7):1504-13
1510447
J Clin Microbiol. 1995 Sep;33(9):2233-9
7494007
Antimicrob Agents Chemother. 1997 Feb;41(2):292-7
9021182